Kymera Therapeutics Inc. (KYMR) is a clinical-stage biotechnology company focused on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins. The company is leveraging its proprietary protein degradation platform, called Pegasus, to advance a pipeline of drug candidates in oncology and immunology indications.
KYMR's lead program, KT-474, is being developed for the treatment of patients with solid tumors harboring specific oncogenic mutations in the KRAS gene. The company also has several other programs in various stages of preclinical and clinical development, including drug candidates for the treatment of patients with autoimmune and inflammatory diseases, as well as additional oncology indications.
KYMR has partnerships with several leading pharmaceutical companies, including Sanofi, Vertex Pharmaceuticals, and GlaxoSmithKline, to develop and commercialize its drug candidates. The company has a strong intellectual property portfolio, with numerous patents and patent applications covering its protein degradation platform and drug candidates.
Headquartered in Cambridge, Massachusetts, KYMR went public in 2020 and is listed on the NASDAQ stock exchange under the ticker symbol KYMR. The company's management team includes experienced leaders from the biotechnology and pharmaceutical industries, including CEO Nello Mainolfi and CSO Jared Gollob.
|
